Patient P-01547

Synthetic patientNBL-101 · Day 109 · 55–64 · F · baseline S13Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Stable

Inflammatory state

Improving

Nutritional resilience

Stable

Discontinuation risk

56%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S13
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 60 GI-04 recommended — GI Support Protocol GI-04
Day 61 Patient accepted — Started GI-04 in the companion
Day 62 ME-01 recommended — Monitoring Escalation ME-01
Day 63 Patient accepted — Started ME-01 in the companion
Day 66 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 69 GI symptom burden −25% vs expected — GI Support Protocol GI-04
Day 75 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

Treatment adherence+7
Inflammatory activity-4
Nutritional resilience-2

What helped?

GI Support Protocol GI-04Day 60
Result: symptom burden −25%
Monitoring Escalation ME-01Day 62
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

51%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 27/100
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 47
Drug metabolism and exposure ↑20
- BloodToxicity index 52

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.1 · butyrate capacity 27/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 47 ms
Sleep: 6.4 h
Steps: 6,231
Resting HR: 70 bpm

Daily log: GI score 48, nutritional resilience 42, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01433	53%	S14	GI-04	improved	48
P-01570	52%	S14	SC-12	improved	46
P-01494	51%	S14	GI-04	improved	42
P-01360	49%	S14	GI-04	improved	52
P-01539	49%	S14	GI-04	improved	43
P-01431	48%	S14	GI-04	improved	41
P-01486	48%	S18	GI-04	improved	47
P-01603	48%	S14	GI-04	improved	40
P-01635	48%	S02	GI-04	improved	49
P-01782	48%	S14	NP-02	no change	48
P-01365	47%	S14	SC-12	improved	49
P-01403	47%	S14	GI-04	improved	49